Introduction {#S1}
============

Chronic obstructive pulmonary disease (COPD) is a disease of enormous and growing global burden^[@R1]^, ranked third as a global cause of death by the World Health Organization in 2016^[@R2]^. Environmental risk factors, predominately cigarette smoking, account for a large fraction of disease risk, but there is considerable variability in COPD susceptibility among individuals with similar smoking exposure. Studies in families and in populations demonstrate that genetic factors account for a substantial fraction of disease susceptibility. Similar to other adult-onset complex diseases, common variants likely account for the majority of population genetic susceptibility^[@R3],[@R4]^. Our previous efforts identified 22 genome-wide significant loci^[@R5]^. Expanding the number of loci can lead to novel insights into disease pathogenesis, not only through discovery of novel biology at individual loci^[@R6],[@R7]^, but also across loci via identification functional links and specific cell types and phenotypes^[@R5]^.

We performed a genome-wide association study combining previously described studies from the International COPD Genetics Consortium (ICGC)^[@R5]^ with additional subjects from the UK Biobank^[@R8]^, a population-based study of several hundred thousand subjects with lung function and cigarette smoking assessment. We determined, through bioinformatic and computational analysis, the likely set of variants, genes, cell types, and biologic pathways implicated by these associations. Finally, we assessed our genetic findings for relevance to COPD-specific, respiratory, and other phenotypes.

Results {#S2}
=======

Genome-wide association study of COPD {#S3}
-------------------------------------

We included a total of 257,811 individuals from 25 studies in the analysis, including studies from International COPD Genetics Consortium and UK Biobank ([Figure 1](#F1){ref-type="fig"}). We defined COPD based on pre-bronchodilator spirometry according to modified Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for moderate to very severe airflow limitation^[@R9]^, as done previously^[@R5]^. This definition resulted in 35,735 cases and 222,076 controls ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). We tested association of COPD and 6,224,355 variants in a meta-analysis of 25 studies using a fixed-effects model. We found no evidence of confounding by population substructure using linkage disequilibrium score regression^[@R10]^ (LDSC) intercept (1.0377, s.e. 0.0094).

We identified 82 loci (defined using 2-Mb windows) at genome-wide significance (*P* \< 5 × 10^−8^) ([Figure 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}; [Supplementary Figures 1](#SD2){ref-type="supplementary-material"} and [2](#SD2){ref-type="supplementary-material"}). Forty-seven of 82 loci were previously described as genome-wide significant in COPD^[@R5],[@R11]^ or lung function^[@R12]--[@R20]^ ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}), leaving 35 novel loci ([Table 1](#T1){ref-type="table"}) at the time of analysis. We then sought to replicate these loci. Given the strong genetic correlation between population-based lung function and COPD, we tested the lead variant at each locus for association with forced expiratory volume in 1 s (FEV~1~)or FEV~1~/forced vital capacity (FVC) in 79,055 individuals from SpiroMeta^[@R21]^ ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). We identified 13 loci - *C1orf87, DENND2D, DDX1, SLMAP, BTC, FGF18, CITED2, ITGB8, STN1, ARNTL, SERP2, DTWD1,* and *ADAMTSL3 --* that replicated using a Bonferroni correction for a one-sided *P* \< 0.05/35; [Table 1](#T1){ref-type="table"}). Although not meeting the strict Bonferroni threshold, additional 14 novel loci were nominally significant in SpiroMeta (consistent direction of effect and one-sided *P* \< 0.05): *ASAP2, EML4, VGLL4, ADCY5, HSPA4, CCDC69, RREB1, ID4, IER3, RFX6, MFHAS1, COL15A1, TEPP,* and *THRA* ([Table 1](#T1){ref-type="table"}), and all 82 loci showed consistent direction of effect with either FEV~1~ or FEV~1~/FVC ratio in SpiroMeta ([Table 1](#T1){ref-type="table"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). We note that 9 of our 35 novel loci were recently described in a contemporaneous analysis of lung function in UK Biobank^[@R21]^. None of the novel loci appeared to be explained by cigarette smoking, and variant effect sizes in ever- and never-smokers and including and excluding self-reported asthmatics were similar ([Supplementary Note](#SD2){ref-type="supplementary-material"}). In addition, we found no significant differences in variant effects by sex ([Supplementary Note](#SD2){ref-type="supplementary-material"}). Including all 82 genome-wide significant variants, we explain up to 7.0% of the phenotypic variance in liability scale, using a 10% prevalence of COPD, acknowledging that these effects are likely overestimated in the discovery sample. This represents up to a 48% increase in COPD phenotypic variance explained by genetic loci compared to the 4.7% explained by 22 loci reported in a recent GWAS of COPD^[@R5]^.

Identification of secondary association signals {#S4}
-----------------------------------------------

We used approximate conditional and joint analysis^[@R22]^ to find secondary signals at each of the 82 genome-wide significant loci. We found 82 secondary signals at 50 loci, resulting in a total of 164 independent associations in 82 loci ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). Of 50 loci containing secondary associations, 33 were at loci previously described for COPD or lung function, and six at Bonferroni-replicated novel loci. Of 82 secondary associations, 20 reached genome-wide significance (*P* \< 5 × 10^−8^) ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). Of 61 novel (not previously described in COPD or lung function) independent associations, 21 reached a region-wise Bonferroni-corrected threshold (one-sided *P* \< 0.05/novel independent association(s) in each locus) in unconditioned associations from SpiroMeta ([Methods](#S13){ref-type="sec"} and [Supplementary Table 4](#SD1){ref-type="supplementary-material"}).

Tissue and specific cell types {#S5}
------------------------------

In determining the tissue in which COPD genetic variants function to increase COPD risk, lung is the obvious tissue to consider. However, COPD is a systemic disease^[@R23],[@R24]^ and within the lung the cell-types collectively contributing to disease pathogenesis are largely unknown. Furthermore, available databases include cell types relevant to lung (e.g. smooth muscle) but from other organs (e.g. the gastrointestinal tract). To identify putative causal tissues and cell types, we assessed the heritability enrichment in integrated genome annotations at the single tissue level^[@R25]^ and tissue-specific epigenomic marks^[@R26]^. Lung tissue showed the most significant enrichment (enrichment = 9.25, *P* = 1.36 × 10^−9^), as previously described, though significant enrichment was also seen in heart (enrichment = 6.85, *P* = 3.83 × 10^−8^) and the gastrointestinal (GI) tract (enrichment = 5.53, *P* = 6.45 × 10^−11^). In an analysis of enriched epigenomic marks, the most significant enrichment was in fetal lung and GI smooth muscle DNase hypersensitivity sites (DHS) (*P* = 6.75 × 10^−8^) and H3K4me1 (*P* = 7.31 × 10^−7^) ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}). To identify the source of association within lung tissue, we tested for heritability enrichment using single-cell chromatin accessibility^[@R27]^ (ATAC-Seq) and gene expression (RNA-Seq) from human^[@R28],[@R29]^ and murine^[@R30]^ lung ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}). Using LD score regression in murine ATAC-Seq data, we found enrichment of chromatin accessibility in several cell types, including endothelial cells (most significant), type 1, and type 2 alveolar cells (the latter among the highest fold-enrichment \[[Supplementary Table 5a](#SD1){ref-type="supplementary-material"}\]). Results using LD score regression^[@R31]^ or SNPsea^[@R32]^ on single-cell RNA-Seq varied, with nominal *P*-values for genes expressed in type 2 alveolar cells, basal-like cells, club cells, fibroblasts and smooth muscle cells ([Supplementary Tables 5b](#SD1){ref-type="supplementary-material"},[c](#SD1){ref-type="supplementary-material"}).

Fine-mapping of associated loci {#S6}
-------------------------------

To identify the most likely causal variants at each locus, we performed fine mapping using Bayesian credible sets^[@R33]^. Including 160 potential primary and secondary association signals (excluding four variants in the major histocompatibility complex \[MHC\] region), 61 independent signals had a 99% credible set with fewer than 50 variants; 34 signals had credible sets with fewer than 20 variants ([Supplementary Figure 3](#SD2){ref-type="supplementary-material"}). Eighteen loci had a single variant with a posterior probability of driving association (PPA) greater than 60% including the *NPNT* (4q24) locus, where the association could be fine-mapped to a single intronic variant, rs34712979 (NC_000004.11:g.106819053G\>A, see [Supplementary Note](#SD2){ref-type="supplementary-material"} and [Supplementary Table 6](#SD1){ref-type="supplementary-material"}). Most sets included variants that overlapped genic enhancers of lung-related cell types (e.g., fetal lung fibroblasts, fetal lung, and adult lung fibroblasts) and were predicted to alter transcription binding motifs ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}). Of 61 credible sets with fewer than 50 variants, eight sets contained at least one deleterious variant. These deleterious variants included 1) missense variants affecting *TNS1, RIN3, ADGRG6, ADAM19, ATP13A2, BTC*, and *CRLF3*; and 2) a splice donor variant affecting a lincRNA - AP003059.2.

Candidate target genes {#S7}
----------------------

In most cases, the closest gene to a lead SNP will not be the gene most likely to be the causal or effector gene of disease-associated variants^[@R34]--[@R36]^. Thus, to identify the potential effector ('target') genes underlying these genetic associations, we integrated additional molecular information including gene expression, gene regulation (open chromatin and methylation data), chromatin interaction, co-regulation of gene expression with gene sets, and coding variant data ([Methods](#S13){ref-type="sec"} and [Figure 3](#F3){ref-type="fig"}).

At 82 loci, 472 genes within +/− 1 Mb of top associated variants were implicated by analysis of least one dataset; 106 genes were implicated by lung gene expression^[@R37],[@R38]^, and an additional 50 genes by \>= 2 other datasets (methylation^[@R39]^, chromatin interaction^[@R40]^, open chromatin regions^[@R41]^, similarity in gene sets^[@R42]^ or deleterious coding variants^[@R43]^ \[[Figure 3](#F3){ref-type="fig"}\]), for a total of 156 genes meeting more stringent criteria. Excluding loci in the MHC region, the median number of potentially implicated genes per locus was four, with a maximum of 17 genes (7q22.1 and 17q21.1). The median distance of implicated genes to top associated variants was 346 Kb. Among 82 loci, 60 (73%) included the nearest gene. We identified 20 genes with supportive evidence from exome sequencing data. Two genes (*ADAM19* and *ADAMTSL3*) were implicated by five datasets ([Figure 3](#F3){ref-type="fig"}) and another two (*EML4* and *RIN3*) were implicated by four datasets. A summary of all genes implicated using these approaches is included in [Supplementary Table 7](#SD1){ref-type="supplementary-material"}.

Associated pathways {#S8}
-------------------

To gain further functional insight of associated genetic loci, we performed gene-set enrichment analysis using DEPICT^[@R42]^. Among 165 enriched gene sets at false discovery rate (FDR) \< 5%, 44% of them were related to the developmental process term, with nominal *P* for lung development of 1.02 × 10^−6^; significant sub-terms included lung alveolus development (*P* = 0.0003) and lung morphogenesis (*P* = 0.0005). We also found enrichment of extracellular matrix-related pathways including laminin binding, integrin binding, mesenchyme development, cell-matrix adhesion, and actin filament bundles. Additional pathways of note included histone deacetylase binding, the Wnt receptor signaling pathway, SMAD binding, the MAPK cascade, and the transmembrane receptor protein serine/threonine kinase signaling pathway. Full enrichment analysis results including the top genes for each DEPICT gene set are shown in [Supplementary Table 8](#SD1){ref-type="supplementary-material"}.

Identification of drug targets {#S9}
------------------------------

GWAS is also useful for identifying drug targets either at the individual gene^[@R18],[@R44],[@R45]^ or genome-wide level^[@R46],[@R47]^. Of 482 candidate target genes, 60 genes could be targeted by at least one approved or in-development drug^[@R48]^, totaling 428 drugs with 144 different modes of action ([Supplementary Table 9](#SD1){ref-type="supplementary-material"}). Druggable targets at novel loci for COPD and lung function included *ABHD6, CDKL2, GSTO2, KCNC4*, *PDHB*, *SLK*, and *TRPM7*. We also identified drugs for repurposing in COPD using transcriptome-wide associations and drug-induced gene expression signatures^[@R49]^ ([Supplementary Note](#SD2){ref-type="supplementary-material"}).

Phenotypic effects of COPD-associated variants {#S10}
----------------------------------------------

To characterize the phenotypic effects of 82 genome-wide significant loci, we performed a phenome-wide association analysis within the deeply phenotyped COPDGene study ([Methods](#S13){ref-type="sec"}). We assessed for common patterns of phenotype associations for the 82 loci by using hierarchical clustering across scaled Z scores of phenotype-variant associations. We identified two clusters of variants differentially associated with two sets of phenotypes ([Supplementary Figure 4](#SD2){ref-type="supplementary-material"}). As these two variant-phenotype clusters appeared to be driven by computed tomography (CT) imaging features, we repeated variant clustering limited to quantitative computed tomography imaging features. We again found two clusters of variants, differentiated by association with quantitative emphysema, emphysema distribution, gas trapping, and airway phenotypes ([Figure 4a](#F4){ref-type="fig"}). Additionally, we evaluated the association of the 82 genome-wide significant variants in a prior GWAS of emphysema and airway quantitative computed tomography features^[@R50]^ ([Supplementary Table 10](#SD1){ref-type="supplementary-material"}).

We also examined all genome-wide significant loci in the NHGRI-EBI GWAS Catalog^[@R51]^ ([Supplementary Figure 5](#SD2){ref-type="supplementary-material"}, [Supplementary Table 11](#SD1){ref-type="supplementary-material"}) and looked for trait-associated variants in linkage disequilibrium (r^2^ \> 0.2) with our lead COPD-associated variants. Many variants were associated with anthropometric measures including height and body mass index (BMI), measurements on blood cells (red and white cells), and cancers. COPD is well known to have many common comorbidities, such as coronary artery disease (CAD), type 2 diabetes mellitus (T2D), osteoporosis, and lung cancer. Of these diseases and 13 additional traits, we confirmed previously reported overall genetic correlation (using linkage disequilibrium score regression^[@R52]^) of COPD with lung function, asthma, and height, and found evidence of modest correlation between COPD and lung cancer ([Supplementary Note](#SD2){ref-type="supplementary-material"}). However, at individual loci, and using more stringent linkage disequilibrium (r^2^ \> 0.6), we found evidence of shared risk factors for these comorbid diseases and COPD including a genome-wide significant variant near *PABPC4* associated with T2D, four variants with CAD (near *CFDP1, DMWD, STN1*, and *TNS1*), and a variant near *SPPL2C* with bone density ([Figure 4b](#F4){ref-type="fig"}).

Overlapping loci with asthma and pulmonary fibrosis {#S11}
---------------------------------------------------

Based on our previous identification of genetic overlap of COPD with asthma, and COPD with pulmonary fibrosis, we examined loci for specific overlap with these two diseases. In asthma, we noted an r^2^ \> 0.2 with one of our variants and previously reported variants at *ID2, ZBTB38, C5orf56, MICA, AGER, HLA-DQB1, ITGB8, CLEC16A,* and *THRA.* In pulmonary fibrosis, in addition to our previously described overlap at *FAM13A*, *DSP*, and 17q21, we noted overlapping associations at *ZKSCAN1* and *STN1* ([Supplementary Table 12](#SD1){ref-type="supplementary-material"}). To more closely examine overlap, we applied a Bayesian method (gwas-pw^[@R53]^) of COPD associations from our current GWAS with previous GWASs of asthma (limited to those of European ancestry) and pulmonary fibrosis^[@R54],[@R55]^. To mitigate the results of including asthma among our COPD cases, we performed analysis for overlap with asthma removing self-reported asthmatics from UK Biobank for this analysis ([Methods](#S13){ref-type="sec"}). We identified 14 shared genome segments (posterior probability \> 70%), 9 with asthma and 5 with pulmonary fibrosis ([Figure 4c](#F4){ref-type="fig"}, [Supplementary Table 13](#SD1){ref-type="supplementary-material"}). In addition to the three segments shared with pulmonary fibrosis identified in the previous study^[@R5]^ (*FAM13A*, *DSP,* and the 17q21 locus -- here nearest *CRHR1*), we identified two new segments including loci near *ZKSCAN1* and *STN1* (formerly known as *OBFC1)*. Shared variants between COPD and pulmonary fibrosis all had an opposite effect (i.e., increasing risk for COPD but protective for pulmonary fibrosis). In asthma, we identified five shared segments in the 6p21--22 regions, as well as *ADAM19, ARMC2, ELAVL2,* and *STAT6*. With the exception of *STAT6*, overlapping variants showed the same direction of effect.

Discussion {#S12}
==========

Genetic factors play an important role in COPD susceptibility. We examined genetic risk of COPD in a genome-wide association study of 35,735 cases and 222,076 controls. We identified 82 genome-wide significant loci for COPD, of which 47 were previously identified in genome-wide association studies of COPD or population-based lung function. Of 35 loci not previously described at the time of analysis, 13 replicated in an independent study of population-based lung function. We used several data sources to attempt to assign causal genes at each locus, identifying 156 genes at 82 loci that were supported by either gene expression or a combination of at least 2 other data sources. Our results identify specific genes, cell types, and biologic pathways for targeted study and also suggest a genetic basis for the clinical heterogeneity seen in COPD.

Our study supports the role of early life events in the risk of COPD. Gene set enrichment analysis identified developmental pathways both specific to the lung (e.g., lung morphogenesis and lung alveolar development) and related to the lung (e.g., the canonical Wnt receptor^[@R56],[@R57]^, the MAPK/ERK, and the nerve growth factor receptor signaling pathways). We also confirmed enrichment of heritability in epigenomic marks of fetal lung. Our findings are consistent with epidemiologic studies demonstrating that a substantial portion of the risk of COPD may develop in early life: genetic variants may set initial lung function^[@R58]^ and patterns of growth^[@R58]--[@R60]^. While further work will be needed to confirm the causal variants and genes affected by our variants, testing the role of these genes in lung development-relevant murine or ex-vivo models -- for example, determining whether the perturbation of these genes changes proliferation and differentiation of lung epithelial progenitors in induced pluripotent cell-derived lung alveolar type 2 cells^[@R44]^ -- could provide experimental evidence of the role of these genes in early life susceptibility. Ultimately, the goal of this work would be to identify targets for or subsets of high risk individuals early in the disease course, or molecular candidates that may affect lung repair and regeneration^[@R61]^.

Apart from genes related to lung development, our analyses highlighted several genes and pathways already of interest in COPD therapy (e.g. *CHRM3* / acetylcholine receptor inhibitors, the *MAPK* pathway) -- supporting the role of genetic analyses in finding therapeutic targets^[@R18],[@R62]^ -- and newer genes that could inform future functional studies. We identified interleukin 17 receptor D (*IL17RD*), as a potential effector gene at the 3p14 locus. Numerous studies have examined the role of IL-17A in COPD^[@R63]^, and IL17RD can differentially regulate pathways employed by IL-17A^[@R64]^. Chitinase acidic (*CHIA*) at 1p13.3, which encodes a protein that degrades chitin^[@R65]^, exhibits lung-specific expression^[@R66],[@R67]^. *CHIA* variants have been associated with FEV~1~^[@R68]^, asthma^[@R69]--[@R72]^, and acid mammalian chitinase activity^[@R71],[@R73]^. We identified several potential effector genes related to extracellular matrix, cell adhesion, cell-cell interactions, and elastin-associated microfibrils^[@R74]--[@R76]^, some of which have been previously identified in studies of lung function^[@R15]^. These include integrin family members that mediate cell-matrix communication (e.g., *ITGA1, ITGA2*, *ITGA8*^[@R77]--[@R79]^), an integrin ligand encoding gene (*NPNT*^[@R80]^), and genes encoding matrix proteins (e.g., *MFAP2* and *ADAMTSL3*). *ADAMTSL3* plays a role in cell-matrix interactions related to the assembly of fibrillin and microfibril biogenesis^[@R81]--[@R83]^ and of our candidate effector genes was supported by the greatest number of bioinformatic analyses. Recombinant forms of other *ADAMTS*-like proteins demonstrate experimental evidence of promoting and enhancing fibrillin and microfibril deposition and assembly^[@R84],[@R85]^. *ADAMTSL3* may play a role in preventing emphysematous destruction of lung tissue by ADAMTS in COPD.

In addition to identifying the effector gene, knowing the effector cell type is critical for functional studies. We identified an overall enrichment of epigenomic marks in lung tissue and smooth muscle (also identified in studies of lung function^[@R16]^). This latter association was found in gastrointestinal tissue cell types; respiratory smooth muscle is absent in the analyzed datasets. We also performed analyses of single-cell data in an attempt to identify the specific lung cell types in which our top variants are potentially functioning. We found evidence for enrichment of several cell types, including but not limited to endothelial cells, alveolar type 2 cells, and basal-like cells. Each of these cell types has been postulated to have a role in the development of COPD^[@R86]--[@R88]^, and our data are consistent with the likely heterogeneity of lung cell types contributing to COPD susceptibility. The lung comprises at least 40 different resident cell types^[@R89]^, most of which are not distinctly represented in these datasets. Thus, while our findings support the investigation of specific cell types for further functional studies, they also highlight the need for profiling of lung-relevant cell types and loci-specific analyses.

Characterization of functional variant effects could lead to better disease subtyping and more targeted therapy for COPD. Cluster analysis on hundreds of COPD-associated features in the more extensively phenotyped COPDGene cohort showed heterogeneous effects of genetic variants on COPD-related phenotypes, including computed tomography (CT) measurements of airway abnormalities and emphysema -- well-described sources of heterogeneity in COPD^[@R90]--[@R92]^. Analyzing hundreds of diseases/traits in GWAS Catalog, we identified overlapping associations with various diseases/traits in multiple organ systems, comorbidities such as coronary artery disease, bone mineral density, and type 2 diabetes mellitus (T2D). The COPD-associated *PABPC4* locus was associated with T2D^[@R93]^ and C-reactive protein (CRP) level^[@R94]^. Although a causal gene in this locus and its contribution to COPD is unknown, its association with T2D may suggest a shared disease pathway and drug targets. Together, the identification of variable COPD risk loci associations with sub-phenotypes and other diseases^[@R95],[@R96]^ may have potential for more nuanced approaches to therapy for COPD. Overall, our phenotype, gene, and pathway analyses illustrate the utility of both searching for enrichment of genetic signals overall, and performing a more detailed identification of the effects of individual variants or groups of variants.

We performed additional specific analysis in two diseases that overlap with COPD, asthma and pulmonary fibrosis. While a genome-wide genetic correlation of COPD and asthma has been previously described^[@R5]^, our analysis is the first to identify specific shared genetic segments between asthma and COPD. While the effects at most of these shared segments were concordant in direction, one of the segments of particular interest was near *STAT6*, which had opposite directions of effect in the two diseases. *STAT6* plays a role in T helper (Th) type 2-dependent inflammation, and is activated by interleukin-4 and interleukin-13 (IL-4 and IL-13)^[@R97]^. IL-13, in turn, has been found to be increased in asthmatic airways^[@R98]^ but decreased in severe emphysema^[@R99]^. In pulmonary fibrosis, variants at all overlapping loci have an opposite direction of effect compared to COPD^[@R5]^. These effects raise the possibility that specific therapies for one disease could increase the risk of the other disease, which may be worth evaluating in treatment trials. The reasons why genetic effects are divergent between COPD and fibrosis are unclear, but these identified opposite effects could point to molecular switches that influence why some smokers develop emphysema while others develop pulmonary fibrosis. While pulmonary fibrosis is an uncommon disease and specifically excluded in several of our COPD case-control cohorts, interstitial lung abnormalities are increasingly being recognized as a potential precursor to fibrosis, and an inverse relationship between these abnormalities and emphysema has been previously identified^[@R100]^. Mechanistically, some have hypothesized that the divergent derangement of Wnt and Notch signaling pathways^[@R101]^ and mesenchymal cell fate^[@R102]^ may be responsible for the distinct development of these two diseases. We also describe an overlapping region at the *STN1* (previously known as *OBFC1*) locus. *STN1* plays a role in telomere maintenance^[@R103]^; shortened telomeres have been observed in both COPD and idiopathic pulmonary fibrosis (IPF)^[@R104],[@R105]^, and rare genetic variants in the telomerase pathway have been implicated in both pulmonary fibrosis and emphysema -- albeit with concordant effects on either disease^[@R106]^.

While our study a large genome-wide association study of COPD, individuals meeting our criteria for COPD in the UK Biobank may be different from other studies, especially for smoking history. We used the same definition of COPD as in our prior analysis^[@R5]^, which included non-smokers. Our use of pre-bronchodilator spirometry to define COPD (allowing us to maximize sample size) as well as population-based lung function for replication could bias our findings against variants that are only associated with more severe forms of COPD. We did not exclude other causes of airway obstruction such as asthma, noting that asthma frequently overlaps with, and is misdiagnosed in COPD^[@R107]^. We performed several additional analyses to determine whether our results were driven by, or markedly different, by smoking status, asthma, or use of pre- instead of post-bronchodilator spirometry to define COPD. The results of these additional analyses did not indicate a substantial impact of these factors on our overall findings, and together with prior analyses^[@R5],[@R16]^, suggest that bias due to these factors is likely small. However, our study was not designed to identify differences between subgroups, and we cannot rule out a role for studying more severe disease or disease subtypes. We note that the alpha-1 antitrypsin locus (*SERPINA1*) was identified as genome-wide significant in smaller studies of emphysema and in smokers with severe COPD^[@R108]^. In the current study, the association of the PiZ allele (NC_000014.8:g.94844947C\>T, rs28929470) had *P* = 2.2 × 10^−5^ using moderate-to-severe cases (FEV~1~ \< 80% predicted), and a smaller *P*-value (1.4 × 10^−6^) in severe cases (FEV~1~ \< 50% predicted) despite a smaller sample size, a phenomenon we have previously described^[@R11]^. Thus, despite the strong overlap of COPD with quantitative spirometry, new loci may be identified through studies of sufficiently large subsets of COPD patients and with more specific and homogeneous COPD phenotypes. Given suggestive evidence for replication using a related (but not identical) phenotype for additional novel loci beyond the 13 meeting a Bonferroni-corrected threshold for significance, we chose to include all loci significant in discovery in subsequent analyses, recognizing that we likely included some false positive associations. Our study focused on relatively common variants, predominantly in individuals of European ancestry; more detailed studies of rare variants, the human leukocyte antigen (HLA) regions, and other ethnicities are warranted, but broader multi-ethnic analyses are limited by the number of cases in currently available cohorts. Although COPD sex differences have been reported^[@R109]^, we did not identify significant sex-specific differences in effect sizes of the 82 top variants. Future studies including more subjects and methodological advances may be needed to elucidate this effect.

The global burden of COPD is increasing. Our work finds a substantial number of new loci for COPD and uses multiple lines of supportive evidence to identify potential genes and pathways for both existing and novel loci. Further investigation of the genetic overlap of COPD with other respiratory diseases and the phenotypic effects of top loci finds new shared loci for asthma and idiopathic pulmonary fibrosis and suggests heterogeneity across COPD-associated loci. Together, these insights provide multiple new avenues for investigation of the underlying biology and the potential therapeutics in this deadly disease.

Methods {#S13}
=======

Study populations {#S14}
-----------------

The UK Biobank is a population-based cohort consisting of 502,682 individuals^[@R8]^. To determine lung function, we used measures of forced expiratory volume in 1 second (FEV~1~) and forced vital capacity (FVC) derived from the spirometry blow volume-time series data, subjected to additional quality control based on ATS/ERS criteria^[@R110]^ ([Supplementary Note](#SD2){ref-type="supplementary-material"}). As in our previous study^[@R5]^, we defined COPD using pre-bronchodilator spirometry according to modified Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for moderate to very severe airflow limitation^[@R9]^: FEV~1~ less than 80% of predicted value (using reference equations from Hankinson et al.^[@R111]^), and the ratio between FEV~1~ and FVC less than 0.7. Consistent with our previous analyses and enrollment criteria for COPD case-control datasets^[@R112]^, we did not exclude individuals based on self-reported asthma. Genotyping was performed using Axiom UK BiLEVE array and Axiom Biobank array (Affymetrix, Santa Clara, California, USA) and imputed to the Haplotype Reference Consortium (HRC) version 1.1 panel^[@R113]^.

We invited participants in the prior International COPD Genetics Consortium (ICGC) COPD genome-wide association study to provide case-control association results (with the exception of the 1958 British Birth Cohort, to avoid overlapping samples with the replication sample). ICGC cohorts performed case-control association analysis based on pre-bronchodilator measurements of FEV~1~ and FEV~1~/FVC, and cases were identified using modified GOLD criteria, as above. Studies were imputed to 1000 Genomes reference panels. Detailed cohort descriptions and cohort-specific methods have been previously published^[@R5]^ ([Supplementary Note](#SD2){ref-type="supplementary-material"}). All studies comply to all relevant ethical regulations. Ethical/regulatory boards approved the study protocol for each study ([Supplementary Note](#SD2){ref-type="supplementary-material"}). We obtained informed consent from all participating individuals.

Based on the strong genetic overlap of lung function and COPD^[@R5]^, we performed lookups of select significant variants for FEV~1~ and FEV~1~/FVC in the SpiroMeta consortium meta-analysis^[@R21]^. Briefly, SpiroMeta comprised a total of 79,055 individuals from 22 studies imputed to either the 1000 Genomes Project Phase 1 reference panel (13 studies) or the HRC (9 studies). Each study performed linear regression adjusting for age, age^[@R2]^, sex, and height, using rank-based inverse normal transforms, adjusting for population substructure using principal components or linear mixed models, and performing separate analyses for ever- and never- smokers or using a covariate for smoking (for studies of related subjects). Genomic control was applied to individual studies, and results were combined using a fixed-effects meta-analysis^[@R21]^.

Genome-wide association analysis {#S15}
--------------------------------

In UK Biobank, we performed logistic regression of COPD, adjusting for age, sex, genotyping array, smoking pack-years, ever smoking status, and principal components of genetic ancestry. Association analysis was done using PLINK 2.0 alpha^[@R114]^ (downloaded on December 11, 2017) with Firth-fallback settings, using Firth regression when quasi-complete separation or regular-logistic-regression convergence failure occurred. We performed a fixed-effects meta-analysis of all ICGC cohorts and UK Biobank using METAL (version 2010--08-01)^[@R115]^. We assessed population substructure and cryptic relatedness by linkage disequilibrium (LD) score regression intercept^[@R10]^. We defined a genetic locus using a 2-Mb window (+/−1 Mb) around a lead variant, with conditional analyses as described below.

To maximize our power to identify existing and discover new loci, we examined all loci at the genome-wide significance value of *P* \< 5 × 10^−8^. We first characterized loci as being previously described (evidence of prior association with lung function^[@R12]--[@R20],[@R116],[@R117]^ or COPD^[@R5],[@R11],[@R118]^) or novel. We defined previously reported signals if they were in the same LD block in Europeans^[@R119]^ and in at least moderate LD (r^2^ \>= 0.2). For novel loci we attempted replication through association of each lead variant with either FEV~1~ or FEV~1~/FVC ratio in SpiroMeta, using one-sided *P*-values with Bonferroni correction for the number of novel loci examined. Novel loci failing to meet a Bonferroni-corrected *P*-value were assessed for nominal significance (one-sided *P* \< 0.05) or directional consistence with FEV~1~ and FEV1/FVC ratio in SpiroMeta.

Cigarette smoking is the major environmental risk factor for COPD and genetic loci associated with cigarette smoking have been reported^[@R5],[@R120]^. While we adjusted for cigarette smoking in our analysis, we further examined these effects by additionally testing for association of each locus with cigarette smoking and by looking at two separate analyses of ever- and never- smokers in UK Biobank. We tested for sex-specific genetic effects of genome-wide significant variants via a stratified analysis and interaction testing, using a 5% Bonferroni-corrected threshold to determine significance ([Supplementary Note](#SD2){ref-type="supplementary-material"}).

Identification of independent associations at genome-wide significant loci {#S16}
--------------------------------------------------------------------------

We identified specific independent associations at genome-wide significant loci using GCTA-COJO^[@R22]^. This method utilizes an approximate conditional and joint analysis approach requiring summary statistics and representative LD information. As the UK Biobank provided the predominant sample, we used 10,000 randomly drawn unrelated individuals from this discovery dataset as a LD reference sample. We scaled genome-wide significance to a 2-Mb region, resulting in a locus-wide significant threshold of 8 × 10^−5^, or 2 × 10^−6^ for variants in the major histocompatibility complex (MHC) region (chr6:28477797--33448354 in hg19). We created regional association plots via LocusZoom using 1000 Genomes EUR reference data^[@R121]^ (Nov2014 release).

Identification and prioritization of tissues and cell types, candidate variants, genes, and pathways {#S17}
----------------------------------------------------------------------------------------------------

### Identification of enriched tissues and specific cell types {#S18}

We used LD Score Regression (LDSC) to estimate the enrichment of functional annotations^[@R26]^ and specifically expressed gene regions^[@R31]^ on disease heritability. We utilized LDSC baseline models (e.g., conserved region, promoter flanking region), tissue-specific annotations from the Roadmap Epigenomics Program^[@R31]^, integrated tissue annotations from GenoSkyline^[@R25]^, and cell type-specific chromatin accessibility data^[@R27]^ (ATAC-Seq). We used four single-cell gene expression (RNA-Seq) datasets to identify specific cell types ([Supplementary Note](#SD2){ref-type="supplementary-material"}), including 1) lung epithelial cells from normal and pulmonary fibrosis human lung^[@R28]^ (Gene Expression Omnibus \[GEO\] accession GSE86618), 2) human induced pluripotent stem cells (iPSCs)-derived putative alveolar type 2 cells^[@R29]^ (GSE96642), 3) mouse lungs at embryonic day 18.5 (E18.5) and 4) postnatal day 1 (P1) by Whitsett et al. (unpublished, available at LungMAP^[@R30]^). We also used SNPsea^[@R32]^ to identify enriched cell types in genome-wide significant loci ([Supplementary Note](#SD2){ref-type="supplementary-material"}). We reported only estimates of coefficients and *P*-values for the Roadmap annotations and gene expression datasets, as theses analyses used --h2-cts, which does not report fold enrichment.

### Fine-mapping of independent association signals at genome-wide significant loci {#S19}

We used Bayesian fine-mapping at each locus to identify the credible set: the set of variants with a 99% probability of containing a causal variant. Briefly, for each genome-wide significant loci we calculated approximate Bayes factors^[@R33]^ of association. We then selected variants in each locus, so that their cumulative posterior probability was equal or greater than 0.99 using an unscaled variance. At loci with multiple independent associations, we used statistics from approximate conditional analysis with GCTA software on each index variant adjusting for other independent variants in the loci. Otherwise, we used unconditioned statistics from our meta-analysis. Details on characterization of variant effects are summarized in the [Supplementary Note](#SD2){ref-type="supplementary-material"}.

### Identification of target genes {#S20}

We used several computational approaches with corresponding available datasets to identify target genes in genome-wide significant loci. We used two methods that utilized gene expression data: 1) S-PrediXcan and 2) DEPICT. We used S-PrediXcan^[@R37]^ to identify genes with genetically regulated expression associated with COPD. We used data from the Lung-eQTL consortium^[@R38]^ (1,038 lung tissue samples) as an expression quantitative trait loci (eQTL) and gene expression reference database. S-PrediXcan tests for association between a trait and imputed gene expression using summary statistics. Here, we performed S-PrediXcan using models for protein-coding genes +/− 1 Mb from top-associated variants at genome-wide significant loci. We used DEPICT (Data-driven Expression Prioritized Integration for Complex Traits)^[@R42]^ to prioritize genes from 'reconstituted' gene sets.

We also used additional information on gene regulation, including epigenetic data: 1) regulatory fine mapping, 2) methylation quantitative trait loci (mQTL), and 3) chromosome conformation capture. We used regulatory fine mapping (regfm^[@R41]^) to overlap 99% credible interval (CI) variants at each GWAS locus with open chromatin regions based on DNAse hypersensitivity sites (DHS). DHS cluster accessibility state was then associated with gene expression levels (for 13,771 genes) from 22 tissues in the Roadmap Epigenomics Project^[@R41]^. Using both the 99% CI and DHS overlap, as well as the DHS state and transcript level association, regfm calculates a posterior probability of association of each gene +/− 1 Mb of the lead SNP at each GWAS locus. We also searched for overlapping mQTL data from lung tissue, as recently described^[@R39]^. To determine whether these signals co-localized (rather than being related due to linkage disequilibrium), we performed colocalization analysis between our GWAS and mQTL in genome-wide significant loci using eCAVIAR^[@R122]^ (eQTL and GWAS CAusal Variants Identification in Associated Regions, [Supplementary Note](#SD2){ref-type="supplementary-material"}). We also sought information from publicly available chromosome conformation capture data^[@R40]^. We queried association statistics of chromatin contact (i.e., long range chromatin interactions) between top associated variants and gene promoters nearby in a lung (fetal lung fibroblast cell line (IMR90) and human lung tissue^[@R40]^) using HUGIn^[@R123]^ (Hi-C Unifying Genomic Interrogator). We retained only the strongest associations (i.e., smallest *P*-value) for each cell line/primary cell in the analysis.

Finally, we searched for signals from deleterious variants by querying consequences of variants within 99% credible sets containing fewer than 50 variants ([Supplementary Note](#SD2){ref-type="supplementary-material"}). We also searched for rare coding variants, based on exome sequencing results in the COPDGene, Boston Early-Onset COPD (BEOCOPD), and International COPD Genetics Network (ICGN) studies, as previously described^[@R43]^. In brief, we performed exome sequencing on 485 severe COPD cases and 504 smoking resistant controls from the COPDGene study and 1,554 subjects ascertained through 631 probands with severe COPD from the BEOCOPD and the ICGN study. Details on statistical tests for single-variant and gene-based analyses are summarized in the [Supplementary Note](#SD2){ref-type="supplementary-material"}.

For each dataset described above, we used Bonferroni-corrected *P*-values, or a fixed posterior probability threshold to determine target genes at each locus. We reported protein-coding genes +/−1 Mb from a top associated variant. We restricted our search to genes from the GRCh37 server in biomaRt^[@R124]^ with updated HUGO Gene Nomenclature Committee (HGNC) names (downloaded from HGNC database of human gene names on June 7, 2018). For each locus, we used a 5% Bonferroni-corrected threshold (i.e., *P* \< 0.05 divided by number of genes at that locus) to determine significance for 4 data types: gene expression data, chromatin conformation capture data, co-regulation of gene expression, and exome sequencing results. For two remaining datasets, we used a fixed posterior probability (of gene association with a GWAS locus) threshold of 0.1 for regfm and eCAVIAR. We considered genes that were implicated by gene expression or \>= 2 combination of other datasets (e.g., methylation and chromatin conformation capture data) as target genes.

### Identification of pathways {#S21}

To identify enriched pathways in COPD-associated loci, we performed gene-set enrichment analysis using the "reconstituted" genes sets from DEPICT, as described above^[@R42]^. We defined significant gene sets using false discovery rate (FDR) \< 5%.

Effects on COPD-related and other phenotypes {#S22}
--------------------------------------------

COPD is a complex and heterogeneous disorder, comprised of different biologic processes and specific phenotypic effects. In addition, many loci discovered by GWAS have pleiotropic effects. To identify these effects, we performed analyses of a) identification of overlapping genetic loci between related disorders (asthma and pulmonary fibrosis) b) genetic association studies of our genome-wide significant findings using COPD-related phenotypes, including a cluster analysis to identify groups of variants that may be acting via similar mechanisms; c) look up of top variants in prior COPD-related quantitative computed tomography (CT) imaging feature GWAS, d) look up of associations with other diseases/traits using GWAS Catalog, and e) estimate the genetic correlation between COPD and other diseases/traits.

To identify overlapping loci between COPD and other respiratory disorders, we used gwas-pw^[@R53]^ to perform pairwise analysis of GWAS. This method searches for shared genomic segments^[@R119]^ using adaptive significance threshold, allowing detection of sub genome-wide significant loci. We identified shared segments or variants using posterior probability of colocalization greater than 0.7^[@R53]^. We obtained GWAS summary statistics from previous studies of pulmonary fibrosis^[@R55]^ and asthma in Europeans^[@R54]^. For the overlap analysis of COPD with asthma, we examined the influence of the inclusion of individuals with self-reported asthma on both the overlap of discrete GWAS loci (using gwas-pw) and genome-wide genetic correlation (using LD score regression) by performing these analyses in the meta-analysis of ICGC studies and the UK Biobank (with individuals with asthma removed from cases in the latter). To assess heterogeneous effects of COPD susceptibility loci on COPD-related features (phenotypes), we evaluated associations of our genome-wide significant SNPs with 121 detailed phenotypes (e.g., lung function, computed tomography-derived metrics, biomarkers, and comorbidities) available in 6,760 COPDGene non-Hispanic whites. We calculated Z-scores for each SNP-phenotype combination relative to the COPD risk allele to create a SNP by phenotype Z-score matrix. We tested each COPD-related phenotype with at least one nominally significant association with one of our genome-wide significant COPD SNPs, leaving us with 107 phenotypes. We then oriented all Z-scores to be positive (based on sign of median Z score) in association with each phenotype to avoid clustering based on direction of association. To avoid clustering phenotypes only by strength of association with SNPs, we scaled Z-scores within each phenotype by subtracting mean Z-scores and dividing by the standard deviation of Z-scores within each phenotype. We then scaled Z-scores across SNPs to circumvent clustering of SNPs according only to relative strength of association with phenotypes. We then performed hierarchical clustering of the scaled Z-scores of associations between SNPs and phenotypes to identify clusters of SNPs and phenotypes for all 107 phenotypes as well as in the subset of 26 quantitative imaging phenotypes. We performed the clustering of variants both in the set of all genome-wide significant variants in discovery as well as in the subset of known variants plus novel variants meeting a strict Bonferroni threshold in SpiroMeta replication ([Supplementary Note](#SD2){ref-type="supplementary-material"}). We further examined top variant associations with COPD-related traits through a look-up of top variants in a prior GWAS of 12,031 subjects with quantitative emphysema and airway CT features^[@R50]^. To examine overlap of our COPD results with other traits, we downloaded genome-wide significant associations from the GWAS Catalog^[@R51]^ (*P* \< 5 × 10^−8^; downloaded on April 10, 2018). Between a pair of COPD- and trait- associated variants within the same LD block in Europeans^[@R119]^, we computed the LD using the European ancestry panel^[@R125]^ and considered the overlap if variants were in at least in moderate LD (r^2^ \>= 0.2). We estimated genetic correlation between COPD and other diseases/traits using a web engine for LDSC, LD Hub^[@R52]^. We assessed the results using a 5% Bonferroni-corrected significance level.

Identification of drug targets {#S23}
------------------------------

We queried our target genes using the Drug Repurposing Hub^[@R48]^. This resource contains comprehensive annotations of launched drugs, drugs in phases 1--3 of clinical development, previously approved and preclinical or tool compounds, curated using publicly available sources (e.g., ChEMBL and Drugbank) and proprietary sources. We performed drug-gene expression similarity analysis^[@R49]^ (the Query) using a ranked gene set from a gene-based association test^[@R37]^ ([Supplementary Note](#SD2){ref-type="supplementary-material"}).

Reporting Summary {#S24}
-----------------

We provide further information on research design in the **Life Sciences Reporting Summary** linked to this article.

Data availability statement {#S25}
===========================

The genome-wide association summary statistics are available at the database of Genotypes and Phenotypes (dbGaP) under accession phs000179.v5.p2 and via the UK Biobank. Derived phenotypic data for COPD case control status is also available in the UK Biobank.
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![Study design\
COPD, chronic obstructive pulmonary disease; FEV~1~, force expiratory volume in one second; FVC, forced vital capacity. ARIC, Atherosclerosis Risk in Communities.](nihms-1517255-f0001){#F1}

![Manhattan plot\
*P*-values are two-sided based on Wald statistics (35,735 cases and 222,076 controls) without multiple comparison adjustment. Loci are labeled with the closest gene to the lead variant.](nihms-1517255-f0002){#F2}

![Identification of target genes\
(a) Overview of datasets used to identify target genes at genome-wide significant loci (b) Regional association plots at *ADAMTSL3* locus showing GWAS (top), chromatin interaction in lung tissue (middle) and expression quantitative trait loci (bottom). GWAS *P*-values are two-sided based on Wald statistics (35,735 cases and 222,076 controls). Expression quantitative trait loci (eQTL) *P*-values are two-sided based on t statistics (1,038 samples). *P*-values for Hi-C data were calculated using binomial distribution from spline-fitted and outlier-filtered distribution of contacts. All *P*-values were not adjusted for multiple comparison. GREx, gene-based association using gene expression; mQTL, colocalization with methylation quantitative trait loci; Cod., significant single variant or gene-based association tests for deleterious coding variants from exome data; Hi-C, significant chromatin interaction identified in human lung or the IMR90 cell line; DHS, overlap with DNase hypersensitivity sites; GSet, prioritized genes from DEPICT.](nihms-1517255-f0003){#F3}

![Effects on COPD-related and other phenotypes\
(a) Heatmap of scaled computed tomography (CT) quantitative imaging associations with the 34 genome-wide significant variants (known and replicated novel associations) with at least nominal (*P* \< 0.05) association with any CT imaging feature in COPDGene non-Hispanic white participants. Cluster 1 variants are more associated with airway imaging features and Cluster 2 variants are more associated with emphysema imaging features. Variants are referred to by the closest gene. (b) Overlap of genome-wide significant loci of COPD and select traits from GWAS Catalog (c) Genome-wide overlapping results between COPD with pulmonary fibrosis (left) and asthma (right). PRM emphysema, emphysema quantified by parametric response mapping; UL, upper lobe of the lung; LL, lower lobe of the lung; Pi10, airway wall thickness calculated from regressing the square root of the airway wall area with the airway internal perimeter. CAD, coronary artery disease; BMD, bone mineral density.](nihms-1517255-f0004){#F4}

###### 

Meta-analysis results showing 35 loci novel for COPD and lung function

  rsID         HGVS name                      Closest gene   Locus      Risk/alt. allele   Risk allele frequency   UK Biobank   ICGC Cohorts   Overall meta-analysis   SpiroMeta FEV1   SpiroMeta FEV1/FVC                                                                     
  ------------ ------------------------------ -------------- ---------- ------------------ ----------------------- ------------ -------------- ----------------------- ---------------- -------------------- --------- ------ ------------ --------- ------- --------- ------- ---------
  rs72673419   NC_000001.10:g.60913143C\>T    *C1orf87*      1p32.1     T/C                0.05                    1.13         1.07--1.18     2.0E-06                 1.19             1.08--1.31           2.9E-04   1.14   1.09--1.19   4.0E-09   −0.02   1.3E-01   −0.05   3.0E-04
  rs629619     NC_000001.10:g.111738108C\>T   *DENND2D*      1p13.3     T/C                0.20                    1.08         1.05--1.11     7.5E-08                 1.10             1.04--1.16           8.2E-04   1.08   1.06--1.11   2.9E-10   −0.01   4.6E-01   −0.02   9.3E-04
  rs10929386   NC_000002.11:g.15906179C\>T    *DDX1*         2p24.3     C/T                0.49                    1.06         1.03--1.08     1.2E-06                 1.07             1.03--1.12           1.8E-03   1.06   1.04--1.08   9.1E-09   −0.02   3.1E-06   −0.02   7.1E-06
  rs62259026   NC_000003.11:g.57746515C\>T    *SLMAP*        3p14.3     C/T                0.75                    1.07         1.04--1.09     1.8E-06                 1.07             1.02--1.12           3.8E-03   1.07   1.04--1.09   2.4E-08   −0.03   3.3E-05   −0.01   6.4E-02
  rs4585380    NC_000004.11:g.75673363G\>A    *BTC*          4q13.3     G/A                0.74                    1.07         1.04--1.10     1.2E-07                 1.06             1.02--1.11           8.1E-03   1.07   1.05--1.09   3.4E-09   −0.02   3.7E-04   −0.02   1.3E-03
  rs12519165   NC_000005.9:g.170901586A\>T    *FGF18*        5q35.1     A/T                0.38                    1.08         1.05--1.10     2.7E-10                 1.02             0.97--1.08           4.0E-01   1.07   1.05--1.09   1.1E-09   −0.02   6.5E-03   −0.03   2.4E-07
  rs646695     NC_000006.11:g.140280398T\>C   *CITED2*       6q24.1     C/T                0.24                    1.07         1.05--1.10     3.0E-08                 1.09             1.04--1.14           3.4E-04   1.08   1.05--1.10   4.6E-11   −0.02   5.6E-04   0.00    7.5E-01
  rs2040732    NC_000007.13:g.20418134C\>T    *ITGB8*        7p21.1     C/T                0.58                    1.07         1.05--1.09     5.2E-09                 1.03             0.99--1.07           1.7E-01   1.06   1.04--1.08   6.9E-09   −0.02   1.8E-03   −0.01   1.0E-02
  rs1570221    NC_000010.10:g.105656874G\>A   *STN1*         10q24.33   A/G                0.35                    1.06         1.03--1.08     3.5E-06                 1.07             1.03--1.12           1.4E-03   1.06   1.04--1.08   2.2E-08   −0.02   9.5E-04   −0.01   3.9E-02
  rs4757118    NC_000011.9:g.13171236C\>T     *ARNTL*        11p15.2    T/C                0.54                    1.07         1.04--1.09     1.1E-08                 1.04             1.00--1.08           7.3E-02   1.06   1.04--1.08   3.8E-09   −0.01   2.8E-01   −0.02   2.2E-03
  rs9525927    NC_000013.10:g.44842503G\>A    *SERP2*        13q14.11   G/A                0.19                    1.07         1.04--1.10     2.9E-06                 1.10             1.05--1.16           1.4E-04   1.08   1.05--1.10   2.8E-09   −0.02   2.2E-02   −0.02   2.2E-03
  rs72731149   NC_000015.9:g.49984710G\>C     *DTWD1*        15q21.2    G/C                0.91                    1.12         1.07--1.17     8.9E-07                 1.12             1.04--1.20           2.6E-03   1.12   1.08--1.16   8.3E-09   −0.05   7.9E-07   −0.03   9.0E-04
  rs10152300   NC_000015.9:g.84392907G\>A     *ADAMTSL3*     15q25.2    G/A                0.23                    1.09         1.06--1.11     2.4E-10                 1.08             1.02--1.13           4.7E-03   1.08   1.06--1.11   4.2E-12   −0.01   6.4E-02   −0.02   1.5E-03
  rs955277     NC_000002.11:g.9290357C\>T     *ASAP2*        2p25.1     T/C                0.61                    1.08         1.05--1.10     2.7E-10                 1.04             0.99--1.08           8.6E-02   1.07   1.05--1.09   1.9E-10   0.00    9.6E-01   −0.01   3.3E-02
  rs12466981   NC_000002.11:g.42433247C\>T    *EML4*         2p21       C/T                0.73                    1.06         1.03--1.08     8.1E-06                 1.08             1.03--1.13           1.2E-03   1.06   1.04--1.09   4.9E-08   −0.01   4.4E-02   −0.01   6.4E-02
  rs2442776    NC_000003.11:g.11640601G\>A    *VGLL4*        3p25.3     G/A                0.15                    1.09         1.06--1.13     5.7E-08                 1.10             1.04--1.16           8.9E-04   1.09   1.06--1.12   2.0E-10   −0.01   6.4E-02   −0.01   1.3E-01
  rs4093840    NC_000003.11:g.123077042T\>A   *ADCY5*        3q21.1     A/T                0.47                    1.07         1.05--1.09     1.6E-09                 1.04             1.00--1.09           4.8E-02   1.06   1.04--1.08   3.9E-10   −0.01   8.5E-02   −0.00   3.8E-01
  rs62375246   NC_000005.9:g.132439010T\>A    *HSPA4*        5q31.1     A/T                0.26                    1.08         1.05--1.10     9.6E-09                 1.03             0.98--1.08           2.7E-01   1.06   1.04--1.09   2.2E-08   −0.02   1.3E-02   −0.01   2.2E-01
  rs979453     NC_000005.9:g.150595073A\>G    *CCDC69*       5q33.1     G/A                0.34                    1.07         1.05--1.10     1.6E-09                 1.02             0.97--1.06           5.1E-01   1.06   1.04--1.08   1.4E-08   −0.01   7.2E-02   −0.00   6.4E-01
  rs1334576    NC_000006.11:g.7211818G\>A     *RREB1*        6p24.3     A/G                0.42                    1.07         1.05--1.09     4.2E-09                 1.02             0.99--1.06           2.2E-01   1.06   1.04--1.08   1.2E-08   0.00    6.9E-01   −0.01   2.9E-02
  rs9350191    NC_000006.11:g.19842661C\>T    *ID4*          6p22.3     T/C                0.85                    1.11         1.08--1.15     6.2E-12                 1.14             1.05--1.23           1.9E-03   1.12   1.09--1.15   5.1E-14   −0.02   4.9E-02   −0.01   1.5E-01
  rs2284174    NC_000006.11:g.30713580T\>C    *IER3*         6p21.33    C/T                0.22                    1.12         1.10--1.15     3.4E-19                 1.12             1.05--1.21           1.5E-03   1.12   1.10--1.15   2.1E-21   −0.01   5.2E-02   −0.02   3.0E-02
  rs674621     NC_000006.11:g.117257018T\>C   *RFX6*         6q22.1     C/T                0.32                    1.06         1.03--1.08     1.3E-06                 1.07             1.03--1.12           1.4E-03   1.06   1.04--1.08   7.6E-09   −0.01   3.6E-02   −0.01   6.9E-02
  rs9329170    NC_000008.10:g.8697658C\>G     *MFHAS1*       8p23.1     C/G                0.86                    1.10         1.06--1.14     2.0E-08                 1.09             1.03--1.15           4.9E-03   1.10   1.07--1.13   3.6E-10   −0.02   4.6E-02   −0.01   6.5E-02
  rs10760580   NC_000009.11:g.101661650G\>A   *COL15A1*      9q22.33    G/A                0.71                    1.08         1.06--1.11     1.6E-10                 1.04             0.99--1.09           1.1E-01   1.07   1.05--1.10   1.2E-10   −0.02   1.5E-02   −0.02   1.4E-02
  rs8044657    NC_000016.9:g.58022625G\>A     *TEPP*         16q21      G/A                0.90                    1.12         1.07--1.16     1.7E-07                 1.09             1.01--1.17           1.8E-02   1.11   1.07--1.15   1.1E-08   −0.02   9.9E-02   −0.02   2.8E-02
  rs62065216   NC_000017.10:g.38218773G\>A    *THRA*         17q21.1    A/G                0.42                    1.06         1.04--1.09     1.2E-07                 1.06             1.01--1.10           2.2E-02   1.06   1.04--1.08   8.1E-09   −0.01   7.8E-02   −0.00   8.0E-01
  rs4660861    NC_000001.10:g.45946636G\>T    *TESK2*        1p34.1     G/T                0.57                    1.05         1.03--1.08     7.2E-06                 1.07             1.03--1.12           1.2E-03   1.06   1.04--1.08   4.4E-08   −0.01   3.0E-01   −0.00   4.1E-01
  rs7650602    NC_000003.11:g.141147414T\>C   *ZBTB38*       3q23       C/T                0.45                    1.07         1.04--1.09     6.7E-09                 1.01             0.97--1.06           5.1E-01   1.06   1.04--1.08   4.9E-08   0.00    8.4E-01   −0.01   3.2E-01
  rs34651      NC_000005.9:g.72144005C\>T     *TNPO1*        5q13.2     C/T                0.08                    1.10         1.06--1.15     7.5E-07                 1.12             1.02--1.22           1.2E-02   1.11   1.07--1.15   3.0E-08   −0.00   7.6E-01   0.00    7.5E-01
  rs798565     NC_000007.13:g.2752152G\>A     *AMZ1*         7p22.3     G/A                0.71                    1.09         1.06--1.11     2.8E-11                 1.00             0.95--1.05           8.8E-01   1.07   1.04--1.09   3.9E-09   −0.01   1.2E-01   −0.00   6.1E-01
  rs7866939    NC_000009.11:g.85126163T\>C    *RASEF*        9q21.32    C/T                0.33                    1.06         1.03--1.08     1.3E-06                 1.07             1.02--1.12           3.8E-03   1.06   1.04--1.08   1.7E-08   −0.01   2.5E-01   −0.01   1.1E-01
  rs7958945    NC_000012.11:g.115947901A\>G   *MED13L*       12q24.21   G/A                0.36                    1.06         1.04--1.09     1.0E-07                 1.07             1.02--1.11           2.8E-03   1.06   1.04--1.09   1.0E-09   −0.01   1.5E-01   −0.00   6.2E-01
  rs72626215   NC_000019.9:g.46294136G\>A     *DMWD*         19q13.32   G/A                0.73                    1.06         1.04--1.09     1.7E-06                 1.11             1.05--1.17           7.3E-05   1.07   1.05--1.10   1.7E-09   0.00    4.8E-01   −0.01   1.2E-01
  rs73158393   NC_000022.10:g.33335386C\>G    *SYN3*         22q12.3    C/G                0.74                    1.06         1.04--1.09     1.1E-06                 1.09             1.03--1.14           1.4E-03   1.07   1.05--1.09   7.7E-09   −0.00   7.7E-01   −0.01   3.3E-01

CI, confidence interval; OR, odds ratio; ICGC, International COPD Genetics Consortium; HGVS, Human Genome Variation Society. This table shows association statistics in UK Biobank (21,081 cases and 179,711 controls), ICGC cohorts (14,654 cases and 42,365 controls), the overall meta-analysis (35,735 cases and 222,076 controls), and SpiroMeta studies (FEV1 and FEV1/FVC; n=79,055). P values are two-sided based on Wald statistics (COPD) and t statistics (FEV1 and FEV1/FVC) without multiple comparison adjustment. White = Significant in SpiroMeta using Bonferroni correction for novel loci (one-sided P \< 0.05/35); Grey = Nominally significant in SpiroMeta (one-sided P \< 0.05), Dark grey = not significant (directionally consistent only)
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